Clinical Study on Mannan Peptide Combined with TP Regimen in Treating Patients with Non-small Cell Lung Cancer

Huai-An Yan¹, Kang Shen¹, Xin-En Huang²*

Abstract

Purpose: To investigate short-term response rate, quality of life and toxicities of mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer (NSCLC). Patients and Methods: Forty one patients with NSCLC were divided into an experimental group treated with TP regimen combined with mannan peptide (21 patients) and a control group treated with TP alone (20 patients). Results: Response rates were 61.9% (13/21) for the experimental and 60% (12/20) for the control group ($p>0.05$). Regarding toxicity, white blood cell decreased more frequently in the control group (65%, 13/20) than in the experimental group (33.3%, 7/21) ($p<0.05$); nausea and vomiting also occurred more frequently in the control group (55%, 11/20 vs 23.8%, 5/21) ($p<0.05$). In terms of quality of life, this index was improved by 57.1% (12/21) and 25% (5/20) in experimental and control groups, respectively ($p<0.05$). Conclusions: Response rate of TP after combined with mannan peptide is mildly increased, while this combination alleviates bone marrow suppression as well as nausea and vomiting of TP, and improves quality of life when treating patients with NSCLC. However, this conclusion should be confirmed by randomized clinical trials.

Keywords: Paclitaxel - cisplatin - mannan peptide - non-small cell lung cancer - toxicity

Introduction

It is estimated that 75% of all lung cancers, a leading cause of cancer-related death worldwide, are of non-small cell lung cancer (NSCLC) type (Qin et al., 2013; Wang et al., 2013). Most patients in China present with locally advanced stage III or IV disease. Although current practice for chemotherapy for this cohort of patients includes several newer generation agents such as vinorelbine, gemcitabine, paclitaxel or docetaxel with a platinum agent, no combination has yet emerged as a gold standard (Non-Small Cell Lung Cancer Collaborative Group, 1995; Schiller et al., 2002). Thus, cytotoxic chemotherapy, especially platinum-based doublet chemotherapy continues to be important treatment for advanced NSCLC (Lustberg et al., 2007; Obasaju et al., 2009). However, according to previous report, when oriental patients with advanced NSCLC were treated with platinum-based chemotherapy, the response rate is proximately 19%, and many of these patients would experience disease progression (Schiller et al., 2002; Yao et al., 2009; Li et al., 2011). It is hypothesized that failure of chemotherapeutic treatment could relate to lower immunological function, multi-drug resistance (MDR) and severe toxicities that discontinue chemotherapy (Gottesman et al., 2002; Illmer et al., 2002). Mannan peptide, is a new immunological enhancer firstly made and in China, and is hypothesized to be associated with none inferior efficacy and low toxicities when combined with chemotherapy. On this background, we retrospectively recruited patients with NSCLC who were treated with chemotherapy alone or combined with mannan peptide, and analyzed the treatment effects and toxicities of Mannan peptide.

Materials and Methods

General information of patients

Forty one patients (25 male, 16 female) pathologically or cytologically diagnosed with lung cancer were retrospectively recruited into this study, including 22 patients with squamous and 19 with adenocarcinoma; average age was 58 years; KPS score> 70 and expected survival time > 6 months. All patients were divided into experimental (21 patients) or control group (20 patients). All patients had imaging examination including CT or MRI before and after treatment.

Treatment

Experimental group was treated with TP regimen combined with mannan peptide (Sinopharma A-Think Pharmaceutical Co., Ltd –manna peptide for injection): paclitaxel 85 mg/m², intravenous infused (iv.) on d1 and d

¹Tumor Department of Siyang People’s Hospital, Suqian. ²Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China. *Equal contributors. *For correspondence: huangxinen06@aliyun.com
**Table 1. Short-term Responsiveness (CR+PR)**

|          | CR   | PR   | SD   | PD   | Response rate (%) |
|----------|------|------|------|------|-------------------|
| Experimental group | 21   | 4    | 9    | 6    | 61.9              |
| Control group     | 20   | 3    | 9    | 5    | 60                |

**Table 2. Incidence of Toxicities in Two Groups (0 - IV degrees)**

| Toxicity            | Incidence (%) |
|---------------------|---------------|
| Nausea and vomiting | 23.8          |
| Leukocytopenia      | 33.3          |

**Table 3. Changes of quality of survival in two groups**

|          | Improved | Stabilized | Decreased | Responsive rate % |
|----------|----------|------------|-----------|-------------------|
| Experimental group | 5       | 7          | 9         | 57.1(12/21)       |
| Control group     | 2       | 3          | 15        | 25 (5/20)         |

**Evaluation of curative effects**

The objective curative effects were evaluated according to RICIST criteria, being divided into complete remission (CR), partial remission (PR), stable (SD) and progression of disease (PD), response rate (RR) was calculated with CR+PR. Toxic reactions were evaluated according to National Cancer Institute-Common Toxicity Criteria (NCI CTC), being divided into Grades 0~4. Quality of life was evaluated according to KPS, increased by 10 score after treatment was considered as improved, decreased by 10 score as declined and unchanged in score as stable.

**Statistical method**

SPSS statistical package (version 11.5) was used. Data between groups were analyzed by χ² test, and p<0.05 was considered statistically significant.

**Results**

**Responsiveness**

Response rate (RR) in experimental group was 61.9% (13/21), while the rate of control group was 60% (12/20), with no statistically significant difference (p>0.05), as shown in Table 1.

**Discussion**

At present, chemotherapy is one of the main methods to treat middle-late staged NSCLC, and the treatment goal is to improve quality of life and prolong survival time. Paclitaxel acts in G2 and M-stage cell cycle, inductions and promotes polymerization of tubulin, prevents depolymerization, stabilizes microtubules, inhibits the formation of spindle and spindle fiber and thus stops proliferation of tumor cell. Paclitaxel combined with cisplatin is associated with higher response rate. However, adverse reactions will increase when these two chemotherapeutic agents combined, including leukocytopenia, nausea and vomiting so that it was difficult for patients to tolerate. Therefore, how to find a regimen that will strengthen the curative effect and improve immunologic function of patients and reduce adverse reaction is an important research direction at present. Mannan peptide is a new immunologic enhancer. Previous studies suggested that mannan peptide is linked with functions to activate phagocyt, NK cell and subgroup of T, B cells and induce unripe interferon and interleukin and cause DNA rupture of tumor cell and viruses and apoptosis of cell (He et al., 2007). It is suggested that mannan peptide is able to enhance phagocytes of mononuclear phagocyte system, activate macrophages and lymphocyte, improve curative effect of chemotherapy, reduce side effects and improve quality of life (He et al., 2007). In this study, mannan peptide combined with chemotherapy was compared with single chemotherapy regarding response rate, adverse effects as well as change of patient quality of life. Our results showed that response rate of mannan peptide group be slightly higher than that in group with chemotherapy alone; the incidence of bone marrow suppression and gastrointestinal side reactions was significantly decreased, with statistically significant difference. The quality of life in experimental group was significantly improved, with statistically significant difference between two groups.

In conclusion, response rate of TP after combined
with mannan peptide is mildly increased, while this combination alleviates bone marrow suppression as well as nausea and vomiting of TP, and improves quality of life when treating patients with NSCLC. However, this conclusion should be confirmed by randomized clinical trials.

Acknowledgements

Dr. Xin-En Huang is supported in part by a grant from Jiangsu Provincial Administration of Chinese Medicine (LZ11091), and in part from a special research fund of Organization Department of Jiangsu Provincial Party Committee, Talent Work Leading Group of Jiangsu Province (333 High-level Talents Training Project).

References

Deng QQ, Huang XE, Ye LH, et al (2013). Phase II trial of Loubo (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. Asian Pac J Cancer Prev, 14, 413-7.

Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.

Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5.

Gottesman MM, Fojo T, Bates SE (2002). Multidrug resistance proteins affect therapy outcome in acute myeloid leukemia patients. Cancer Res, 62, 4955-62.

Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 11, 1059-62.

Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.

Li CG, Huang XE, Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.

Lu YY, Huang XE, Xu L, et al (2013). Potential Predictors of Sensitivity to Pemetrexed as First-line Chemotherapy for Patients with Advanced Non-Squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8.

Obasaju CK, Raju RN, Stinchcombe T, et al (2009). Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIb/IV non-small-cell lung cancer (NSCLC). J Clin Oncol, 27, s416.

Qin HF, Qu LL, Liu H, et al (2013). Serum CEA level change and its significance before and after gefitinib therapy on patients with advanced non-small-cell lung cancer. N Engl J Med, 364, 92-8.

Shu J, Li CG, Liu YC, et al (2012). Comparison of Serum Tumor Associated Material (TAM) with Conventional Biomarkers in Cancer Patients. Asian Pac J Cancer Prev, 13, 2399-403.

Wang WJ, Tso Z, Gu W, et al (2013). Clinical observations on the association between diagnosis of lung cancer and serum tumor markers in combination. Asian Pac J Cancer Prev, 14, 4369-71.

Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotheraphy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22.

Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.

Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.

Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. *Asian Pac J Cancer Prev*, 13, 2349-54.

Xu X, Wang L, Xu HQ, et al (2013). Clinical Comparison between Paclitaxel Liposome (Lipusu) and Paclitaxel for Treatment of Patients with Metastatic Gastric Cancer. *Asian Pac J Cancer Prev*, 14, 2591-4.

Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. *Asian Pac J Cancer Prev*, 11, 1115-8.

Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. *Asian Pac J Cancer Prev*, 12, 2291-4.

Yao CY, Huang XE, Li C, et al (2009). Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. *Asian Pac J Cancer Prev*, 10, 859-64.

Yin HT, Tian QZ, Guan L (2013). In vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. *Asian Pac J Cancer Prev*, 14, 1703-6.

Yin HT, Zhang DG, Wu XL (2013). In vivo evaluation of curcumin-loaded nanoparticles in a A549 xenograft mice model. *Asian Pac J Cancer Prev*, 14, 409-12.

Yu DS, Huang XE, Zhou JN, et al (2012). A Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. *Asian Pac J Cancer Prev*, 13, 2339-40.

Zhan YP, Huang XE, Cao J (2012). Clinical safety and efficacy of Kanglaite (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer. *Asian Pac J Cancer Prev*, 13, 5319-21.

Zhan YP, Huang XE, Cao J (2012). Clinical study on safety and efficacy of Qinin (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer. *Asian Pac J Cancer Prev*, 13, 4773-6.

Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. *Asian Pac J Cancer Prev*, 12, 81-5.

Zhang XZ, Huang XE, Xu YL, et al (2012). Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis. *Asian Pac J Cancer Prev*, 13, 2415-8.

Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. *Asian Pac J Cancer Prev*, 10, 1147-50.